Understanding the Resistance to Enzalutamide in Patients with Castrate Resistant Metastatic Prostate Cancer

Overview

About this study

We are checking for circulating tumor cells at baseline, one month and at progression of disease

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults 18+
  • History of metastatic CRPC with clinical indication to start treatment with either abiraterone acetate/prednisone or enzalutamide

Exclusion Criteria:  N/A

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Winston Tan, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20463505

Mayo Clinic Footer